Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants

SARS-CoV-2 variants have posed significant challenges to the hopes of using ancestral strain-based vaccines to address the risk of breakthrough infection by variants. We designed and developed a bivalent vaccine based on SARS-CoV-2 Alpha and Beta variants (named SCTV01C). SCTV01C antigens were stabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Rui, Huang, Xun, Cao, Tianshu, Sun, Chunyun, Luo, Dan, Qiu, Hongying, Wu, Mei, Huang, Xingyao, Yu, Chulin, Li, Jing, Kong, Desheng, Ma, Juan, Zhang, Xiao, Hu, Ping, Zhang, Yanjing, Luo, Chunxia, Zhao, Hui, Li, Yuchang, Deng, Yongqiang, Qin, Chengfeng, Xie, Liangzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486464/
https://www.ncbi.nlm.nih.gov/pubmed/36174448
http://dx.doi.org/10.1016/j.virol.2022.09.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486464/
https://www.ncbi.nlm.nih.gov/pubmed/36174448
http://dx.doi.org/10.1016/j.virol.2022.09.003

Ejemplares similares